Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 115 clinical trials
None
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

hydroxyurea
thrombocytosis
neutrophil count
interferon
platelet count
  • 0 views
  • 17 Oct, 2021
  • 62 locations
None
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

disease (in the absence of a validated second line therapy). The main goal of this study is to evaluate for these patients the clinical benefit of a maintenance treatment in patients with stable

  • 0 views
  • 22 Sep, 2021
  • 13 locations
None
A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

toxicity. In case of unsatisfactory response second-line therapy will be initiated. In the absence of unacceptable toxicity, doxycycline administration will be continued for the entire duration of follow

  • 26 views
  • 28 Jan, 2021
  • 8 locations
None
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more …

cancer chemotherapy
tumor cells
conventional surgery
doxorubicin
ifosfamide
  • 103 views
  • 07 Nov, 2020
  • 9 locations
None
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy

  • 0 views
  • 27 Jan, 2021
  • 19 locations
None
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

This is a randomized phase II non comparative study. Patients with metastatic Neuroendocrine Carcinomas (NEC) Grade 3, will be enrolled in the study and will be randomly assigned to receive FOLFIRI or CAPTEM as second line treatment. Disease control rate (DCR) and safety are primary objectives, secondary objectives are Disease …

temozolomide
metastasis
neutrophil count
ki-67
measurable disease
  • 28 views
  • 07 Mar, 2021
  • 23 locations
None
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related mortality both in men and women worldwide. The past few years have demonstrated great progress in the field of tumor immunotherapy through agents that address mechanisms of immune escape notably, so called immune checkpoint inhibitors (ICB). …

  • 0 views
  • 19 Jun, 2021
  • 7 locations
None
Study in Patients With Chronic Leukemia Where Previous Therapy Failed and Who Will be Treated With Ponatinib as Second Line Therapy

treatment in patients failing or not tolerating first line therapy with any other approved TKIs. It is expected that Ponatinib, due to its efficacy, may be more effective as second line therapy than other

  • 0 views
  • 24 Sep, 2021
  • 10 locations
None
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

This phase III study is designed to evaluate the anticancer activity of capmatinib in combination with osimertinib compared to platinum-pemetrexed based doublet chemotherapy as second line treatment in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, T790M negative, mesenchymal-to-epithelial transition factor (MET) …

epidermal growth factor
cancer chemotherapy
growth factor
measurable disease
osimertinib
  • 0 views
  • 07 Oct, 2021
  • 1 location
None
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors

patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.

  • 0 views
  • 22 Sep, 2021
  • 1 location